drugset / Trial / NCT01165931

Coronary Vasomotor Response After Riociguat Exposure

NCT01165931

Phase 2 Withdrawn Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Timeline

Start
2012-05
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Riociguat Other / unclassified 0.1 mg Other